Wedbush Equities Analysts Reduce Earnings Estimates for FHTX

Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) - Investment analysts at Wedbush decreased their Q2 2025 earnings estimates for shares of Foghorn Therapeutics in a research note issued to investors on Wednesday, May 14th. Wedbush analyst R. Driscoll now anticipates that the company will post earnings per share of ($0.31) for the quarter, down from their previous forecast of ($0.28). The consensus estimate for Foghorn Therapeutics' current full-year earnings is ($1.55) per share. Wedbush also issued estimates for Foghorn Therapeutics' Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.26) EPS, FY2025 earnings at ($1.20) EPS, FY2026 earnings at ($1.06) EPS, FY2027 earnings at ($1.07) EPS, FY2028 earnings at ($0.53) EPS and FY2029 earnings at $1.10 EPS.

FHTX has been the subject of several other research reports. HC Wainwright raised Foghorn Therapeutics to a "strong-buy" rating in a report on Wednesday, May 14th. Citizens Jmp initiated coverage on shares of Foghorn Therapeutics in a research note on Wednesday, April 23rd. They issued a "mkt outperform" rating and a $9.00 target price for the company. Citigroup initiated coverage on shares of Foghorn Therapeutics in a research note on Wednesday, April 23rd. They issued an "outperform" rating for the company. B. Riley initiated coverage on shares of Foghorn Therapeutics in a research note on Thursday, January 30th. They issued a "buy" rating and a $10.00 price objective for the company. Finally, JMP Securities reiterated a "market outperform" rating and issued a $9.00 price objective on shares of Foghorn Therapeutics in a research note on Thursday, May 15th. One analyst has rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Foghorn Therapeutics currently has an average rating of "Buy" and an average target price of $12.13.

Foghorn Therapeutics Stock Performance

FHTX remained flat at $4.14 during trading hours on Monday. The company had a trading volume of 70,400 shares, compared to its average volume of 141,045. The firm's 50-day simple moving average is $3.94 and its two-hundred day simple moving average is $5.04. Foghorn Therapeutics has a 52 week low of $2.94 and a 52 week high of $10.25. The stock has a market capitalization of $230.77 million, a PE ratio of -2.16 and a beta of 3.13.

Foghorn Therapeutics (NASDAQ:FHTX - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.30). The firm had revenue of $5.95 million during the quarter, compared to analysts' expectations of $4.96 million.

Hedge Funds Weigh In On Foghorn Therapeutics

A number of large investors have recently modified their holdings of FHTX. Barclays PLC boosted its holdings in Foghorn Therapeutics by 191.6% in the 3rd quarter. Barclays PLC now owns 39,920 shares of the company's stock valued at $371,000 after purchasing an additional 26,228 shares during the period. China Universal Asset Management Co. Ltd. bought a new stake in Foghorn Therapeutics during the fourth quarter valued at $56,000. Wingate Wealth Advisors Inc. bought a new stake in shares of Foghorn Therapeutics during the 4th quarter valued at about $134,000. Rhumbline Advisers boosted its position in shares of Foghorn Therapeutics by 9.1% during the 4th quarter. Rhumbline Advisers now owns 36,384 shares of the company's stock valued at $172,000 after acquiring an additional 3,049 shares during the last quarter. Finally, Los Angeles Capital Management LLC bought a new stake in shares of Foghorn Therapeutics during the 4th quarter valued at about $75,000. 61.55% of the stock is currently owned by institutional investors.

Foghorn Therapeutics Company Profile

Foghorn Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.